Chordia Therapeutics Inc. (190A) Price & Analysis

Compare

2 Followers

190A Stock Chart & Stats

¥108.00

-¥9.00(-2.81%)

At close: Jan 08 4:00 PM EST

¥108.00

-¥9.00(-2.81%)

Day’s Range― - ―

52-Week Range¥98.00 - ¥284.00

Previous CloseN/A

Volume2.20M

Average Volume (3M)565.44K

Market Cap

¥9.25B

Enterprise Value¥6.92B

Total Cash (Recent Filing)¥2.55B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Apr 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.24

Shares Outstanding71,167,900

10 Day Avg. Volume542,310

30 Day Avg. Volume565,443

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)5.07

Price to Sales (P/S)0.00

P/FCF Ratio-6.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageHaving no reported debt materially reduces financial risk and preserves strategic flexibility. For a pre-revenue/early-stage biotech this lowers fixed obligations, making it easier to prioritize R&D spending, negotiate partnerships, and access equity or non-debt financing without immediate interest burdens.

Demonstrated Revenue/Profitability (2023)The 2023 profit result shows the company can generate commercial revenue and positive earnings under the right conditions. This historical capability supports credibility with partners and investors and indicates programs or commercialization paths can translate into cash generation if clinical development and market access progress.

Focused Oncology PipelineA concentrated oncology small-molecule strategy targets high unmet medical needs where durable demand, premium pricing and partnership interest persist. Specialty focus can create deep domain expertise, clearer go-to-market paths, and greater opportunity for licensing or collaboration deals that sustain long-term value creation.

Bears Say

Zero Recent RevenueThe reversion to zero revenue eliminates internal funding for R&D and operations and reduces visibility into future cash flows. Sustained no-revenue periods increase reliance on external financing, heighten dilution risk, and constrain the company’s ability to execute multi-year clinical programs without raising capital.

Sustained Cash BurnLarge negative operating cash flows in consecutive years indicate ongoing high cash consumption relative to resources. Persistent burn pressures the cash runway, forces frequent financing needs, and can compel prioritization or cutbacks in programs, undermining long-term R&D continuity and strategic optionality.

Declining Equity BaseA materially shrinking equity base reflects accumulated losses and weakens the company’s capital cushion. Reduced equity limits ability to absorb setbacks, increases sensitivity to future dilution when raising capital, and may constrain counterparty confidence and partnership bargaining power over the medium term.

Chordia Therapeutics Inc. News

Chordia Advances Rogocekib Leukemia Trial With FDA-Aligned Expansion Cohorts

Chordia Therapeutics Inc. ( ($JP:190A) ) has issued an announcement. Chordia Therapeutics Inc., a Japan-based oncology-focused biopharmaceutical developer,...

13d ago

190A

Chordia Regains Full Rights to CTX-177 After Ending Ono License Deal

Chordia Therapeutics Inc. ( ($JP:190A) ) just unveiled an update. Chordia Therapeutics has formally terminated its license agreement...

21d ago

190A

Chordia Therapeutics’ Major Shareholder Diluted Below 10% After Warrant Exercises

The latest update is out from Chordia Therapeutics Inc. ( ($JP:190A) ). Chordia Therapeutics has announced a change...

1M ago

190A

Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink

Chordia Therapeutics Inc. ( ($JP:190A) ) has shared an announcement. Chordia Therapeutics reported non-consolidated results for the quarter...

2M ago

190A

Chordia Therapeutics to Record Grant Income in Fiscal Year 2026

Chordia Therapeutics Inc. ( ($JP:190A) ) just unveiled an announcement. Chordia Therapeutics Inc. announced the recording of non-operating...

3M ago

190A

Chordia Therapeutics’ CTX-712 Study: A Potential Breakthrough in AML and HR-MDS Treatment

Chordia Therapeutics Inc. (($JP:190A)) announced an update on their ongoing clinical study. Chordia Therapeutics Inc. is conducting a...

4M ago

190A

Chordia Therapeutics Restructures Capital to Strengthen Financial Foundation

Chordia Therapeutics Inc. ( ($JP:190A) ) has shared an announcement. Chordia Therapeutics Inc. announced a strategic financial restructuring...

5M ago

190A

Chordia Therapeutics Reports Fiscal Year 2025 Financial Results

The latest announcement is out from Chordia Therapeutics Inc. ( ($JP:190A) ). Chordia Therapeutics Inc. reported its financial...

5M ago

190A

Chordia Therapeutics Reports Continued Losses in Latest Financial Results

The latest announcement is out from Chordia Therapeutics Inc. ( ($JP:190A) ). Chordia Therapeutics Inc. reported its non-consolidated...

8M ago

190A

Chordia Therapeutics Secures Grant for Cancer Therapy Research

Chordia Therapeutics Inc. ( ($JP:190A) ) has issued an update. Chordia Therapeutics Inc. announced it has received a...

9M ago

190A

190A FAQ

What was Chordia Therapeutics Inc.’s price range in the past 12 months?

Chordia Therapeutics Inc. lowest stock price was ¥98.00 and its highest was ¥284.00 in the past 12 months.

What is Chordia Therapeutics Inc.’s market cap?

Chordia Therapeutics Inc.’s market cap is ¥9.25B.

When is Chordia Therapeutics Inc.’s upcoming earnings report date?

Chordia Therapeutics Inc.’s upcoming earnings report date is Apr 10, 2026 which is in 30 days.

How were Chordia Therapeutics Inc.’s earnings last quarter?

Chordia Therapeutics Inc. released its earnings results on Jan 20, 2026. The company reported -¥4.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.24.

Is Chordia Therapeutics Inc. overvalued?

According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Chordia Therapeutics Inc. pay dividends?

Chordia Therapeutics Inc. does not currently pay dividends.

What is Chordia Therapeutics Inc.’s EPS estimate?

Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Chordia Therapeutics Inc. have?

Chordia Therapeutics Inc. has 71,167,900 shares outstanding.

What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?

Chordia Therapeutics Inc. reported an EPS of -¥4.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?

Currently, no hedge funds are holding shares in JP:190A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Chordia Therapeutics Inc.

Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.